Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Nicotinamide Riboside Chloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Niagen Bioscience, USP Develop First NRCl Monograph
    Niagen Bioscience, USP Develop First NRCl Monograph

    09 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-09/niagen-bioscience-collaborates-with-usp-to-establish-first-ever-usp-monograph-for-nicotinamide-ribos

    PHARMIWEB
    09 Apr 2026
    Share Share
    ChromaDex Expands Niagen® IV And Injection Offerings
    ChromaDex Expands Niagen® IV And Injection Offerings

    10 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240910527761/en

    BUSINESSWIRE
    10 Sep 2024
    Share Share
    ChromaDex To Launch IV And Injectable Niagen At Wellness Clinics
    ChromaDex To Launch IV And Injectable Niagen At Wellness Clinics

    16 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240716150746/en

    BUSINESSWIRE
    16 Jul 2024
    Share Share
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharma-Grade IV & Inj Niagen
    ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharma-Grade IV & Inj Niagen

    13 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240613823864/en

    BUSINESSWIRE
    13 Jun 2024
    Share Share
    ChromaDex Gets US Orphan, Rare Pediatric Status For NRC In AT
    ChromaDex Gets US Orphan, Rare Pediatric Status For NRC In AT

    07 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240607042855/en

    BUSINESSWIRE
    07 Jun 2024
    Share Share
    ChromaDex wins orphan designation for rare ataxia drug
    ChromaDex wins orphan designation for rare ataxia drug

    07 Jun 2024

    // Justine Ra PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/chromadex-wins-orphan-designation-for-rare-ataxia-drug/

    Justine Ra PHARMACEUTICAL TECHNOLOGY
    07 Jun 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.